As of mid-2024, Australia’s prothrombin complex concentrate (PCC) has been replaced by the new 4-factor PCC (Factors II, VII, IX, X) BERIPLEX P/N (international plasma). From February 2025, there has been a transition to BERIPLEX AU (Australian plasma) with discontinuation of BERIPLEX P/N.
In the event that a facility has insufficient vials of one specific BERIPLEX product to make up a dose, the recommendation is BERIPLEX P/N and BERIPLEX AU should not be given as a single dose and should not be mixed in the same syringe. Although not recommended, in a critical emergency if a patient requires treatment with both products they should be administered sequentially and the intravenous line should be flushed between treatments. The batch numbers of the products given must be recorded to enable traceability in case of an adverse event.